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OBJECTIVES The aims of this study were to compare mortality and clinical events following percutaneous
coronary intervention (PCI) between nondiabetics and diabetics with and without proteinuria.
BACKGROUND Diabetics have increased rates of late myocardial infarction, repeat revascularization and
mortality when compared with nondiabetics following PCI. Proteinuria is a marker for
diabetic nephropathy and potentially a surrogate marker for advanced atherosclerosis. It is
unknown if proteinuria is a predictor of outcome in diabetics following PCI.
METHODS We performed an observational study of 2,784 patients who underwent PCI at the Cleveland
Clinic between January 1993 and December 1995. There were 2,247 nondiabetics and 537
diabetics with urinalysis and follow-up data available (proteinuria n 5 217, nonproteinuria
n 5 320). The diabetic proteinuria group was further prospectively stratified into low
concentration (n 5 182) and high concentration (n 5 35). The end points were all-cause
mortality and the composite end point of death, nonfatal myocardial infarction (MI) and need
for revascularization.
RESULTS The mean follow-up time was 20.2 months. The two-year mortality rate was 7.3% and 13.5%
for nondiabetics and diabetics, respectively (p , 0.001). The two-year mortality rate was 9.1%
and 20.3% for the nonproteinuria and proteinuria groups, respectively (p , 0.001). There was
a graded increase in mortality comparing the diabetic group. The two-year mortality rate was
9.1%, 16.2% and 43.1% for the nonproteinuria, low concentration and high concentration
groups, respectively (p , 0.001). The difference in survival between the nondiabetic and
nonproteinuric diabetics was not significant (p 5 0.8).
CONCLUSIONS The presence of proteinuria is the key determinant of risk following PCI for diabetics.
Diabetics without evidence of proteinuria have similar survival compared with nondiabetics.
(J Am Coll Cardiol 1999;33:1269–77) © 1999 by the American College of Cardiology
Diabetes affects more than 100 million patients worldwide
(1). Whether insulin or noninsulin dependent, diabetes is a
critical independent risk factor for atherosclerotic coronary
artery disease (2,3). In fact, over 80 percent of all deaths in
diabetic patients are due to complications from atheroscle-
rosis (4). Given the high prevalence of coronary artery
disease in diabetics, the need for coronary artery revascular-
ization is frequent. Although the initial success and com-
plication rates among diabetic and nondiabetic patients
following percutaneous coronary revascularization are sim-
ilar, diabetics have increased rates of late myocardial infarc-
tion, repeat revascularization and mortality when compared
with nondiabetics (5–7). Diabetes is the most important risk
factor for angiographic and clinical restenosis following
percutaneous coronary revascularization. Overall, the odds
ratio for restenosis among diabetics is 1.35 relative to their
nondiabetic counterparts.
Proteinuria is an important marker for diabetic nephrop-
athy and potentially a surrogate marker for advanced ath-
erosclerosis. The aims of this study were to compare
mortality and clinical event rates following percutaneous
coronary intervention (PCI) between nondiabetics and di-
abetics with and without proteinuria. Therefore, we per-
formed an analysis of all patients who underwent percuta-
neous coronary revascularization at the Cleveland Clinic
from January 1993 through December 1995.
METHODS
Study population. We identified 2,784 patients who un-
derwent percutaneous coronary revascularization at the
Cleveland Clinic Foundation and were flagged for long-
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term follow-up. Only the first 1,000 patients undergoing
PCI in the calendar year are designated for follow-up in the
interventional registry; of this group 2,247 were nondia-
betic. There were originally 714 diabetic patients who had
both short and long-term follow-up data available. We were
able to obtain urinalysis information on 537 patients. This
group of 2,784 patients (2,247 nondiabetics and 537 dia-
betics) was the focus of our study.
Interventional registry. Patients undergoing percutaneous
coronary revascularization at the Cleveland Clinic have been
entered prospectively into an interventional registry (8).
There are dedicated personnel that enter information on
baseline demographic, clinical and angiographic character-
istics into this registry. Initial follow-up information is
obtained by telephone contact with patients at 30 days.
Thereafter, patients are contacted at 12-month intervals for
up to five years following the initial procedure. Follow-up
data include information concerning need for repeat revas-
cularization (either PCI or coronary artery bypass grafting
[CABG]), nonfatal myocardial infarction (MI) and mortal-
ity. These data are collected and recorded by personnel
dedicated solely to the interventional database.
Clinical data. The decision regarding whether patients
underwent PCI, CABG or medical treatment was made by
the attending physician at the time of angiography. Of
patients referred for PCI, the majority underwent balloon
angioplasty, although coronary artery stenting, directional
coronary atherectomy, excimer laser, extraction and rota-
tional atherectomy were also utilized at the discretion of the
operator. Patients only underwent follow-up angiography if
clinically indicated as determined by their attending physi-
cian or if required by enrollment in a randomized controlled
trial.
The baseline clinical characteristics of the study groups
were obtained from the Cleveland Clinic Interventional
Registry. Acute MI was defined as myocardial infarction
within 24 h and recent MI was within 1 to 14 days of PCI.
Angina was defined according to the Canadian Cardiovas-
cular Society. Patients with diabetes were identified from
the registry if they were coded as having either insulin or
noninsulin requiring diabetes. The noninsulin group could
have been treated with either oral hypoglycemic agents or by
diet alone. Patients were coded as having hypertension if
they were diagnosed prior to PCI.
Angiographic data. One or two observers using a caliper
technique determined the severity of coronary stenosis (8).
Significant stenosis was defined as greater than 50% stenosis
in a major epicardial artery. The calcification score was
defined by subjective visual assessment. Zero indicated that
there was no visible calcification, 1 5 faintly visible, 2 5
moderate and 3 5 severe. Chronic total occlusion was
defined as a vessel known to be occluded for $3 months.
Ostial stenosis was any lesion within 2 mm from the ostium.
The lesions were also characterized by the modified (Amer-
ican College of Cardiology/American Heart Association)
ACC/AHA classification scores. Procedure success required
all treated sites to have a less than 50% residual stenosis and
.TIMI (thrombolysis in myocardial infarction) grade two
flow. Complete revascularization required vessels greater
than 1.5 mm with greater than a 50% stenosis to be
successfully treated to less than a 50% residual stenosis and
a total decrease in the stenosis of greater than 20%. Left
ventricular ejection fraction (LVEF) was determined by left
ventriculography when available. Echocardiography was
used if patients did not have a left ventriculogram.
Study design. This was an observational study. All the
baseline clinical, angiographic and end point data elements
were collected prospectively by personnel dedicated to the
interventional registry. As urinalysis data were not recorded
in the interventional registry, proteinuria was obtained
retrospectively from a laboratory computer system by an
investigator blinded to the outcomes of the study patients.
Proteinuria. The presence of proteinuria was determined
by a random urinalysis during the evaluation of this group of
patients at the Cleveland Clinic. It was predetermined that
the urinalysis needed to be within a time frame of six
months prior to and three months postpercutaneous coro-
nary intervention. Urinalyses done within 48 h after the
intervention were not used in data analysis, owing to a
higher false positive rate in patients given intravenous
contrast. Further, the color indicator approximates a trace
reading when the specific gravity is elevated. Such is the case
when patients have had nothing by mouth for 12 to 24 h
prior to angiography. If more than one urinalysis was
available, the highest grade for proteinuria was used. Bayer’s
Multistix 10 SG reagent strips (Bayer Corporation, Elkhart,
Illinois) were used for the urinalysis. The test for proteinuria
is based on the protein-error-of-indicators principle. The
color indicator ranges from yellow (negative for protein) to
yellow green to green to blue for positive reactions. Each
color was semiquantified by laboratory personnel as trace,
11, 21, 31 or greater than 31, without knowledge of the
clinical outcome.
Proteinuria in diabetic patients has been traditionally di-
vided into micro- and macroalbuminuria. Microalbuminuria is
defined as a 24 h protein excretion of 30 to 300 mg/24 h.
Macroalbuminuria is defined as greater than 300 mg/24 h.
In this study, we used routine urinalysis chemstix that only
identified those patients with macroalbuminuria. These
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
CABG 5 coronary artery bypass grafting
LVEF 5 left ventricular ejection fraction
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chemstix generally only identify spot urine albumin to
creatinine ratios greater than 300 mg albumin per mg
creatinine which fall into the macroalbuminura range on
timed urinalysis.
End points. The predetermined end points of this study
were all cause mortality and the composite end point of
death, nonfatal myocardial infarction and need for repeat
revascularization, either PCI or CABG. It was decided
apriori to analyze the end points in two ways with respect to
proteinuria. In the first analysis, the proteinuria was strati-
fied into two groups: proteinuria and nonproteinuria. In the
second analysis, proteinuria was stratified into three groups:
nonproteinuria, low concentration and a high concentra-
tion. The low concentration group had a urinary protein
concentration of trace, 11 or 21. The high concentration
group had a urinary protein concentration of $31. Com-
parison groups included nondiabetics, diabetics and diabet-
ics stratified by proteinuria.
Statistical analysis. Data are listed as mean 6SD or
median and interquartile range if nonnormally distributed.
Statistical analysis was conducted using SYSTAT version
7.0.1 (SPSS Inc., Evanston, Illinois). The Student t test was
used for continuous variables and the chi-square test for
categorical variables. The end points were analyzed using
Cox proportional hazards estimation and presented as
Kaplan-Meier freedom from event survival curves. A mul-
tivariable Cox proportional hazards model was developed
for the end point of death with backward entry of the
following covariates: acute myocardial infarction, insulin
requiring diabetes mellitus, serum creatinine, LVEF, num-
ber of diseased vessels, treatment score and the presence of
proteinuria. A treatment score was developed based on
whether the following medications were given to diabetic
patients: beta-adrenergic blocking agents, angiotensin-
converting enzyme inhibitors (ACE), aspirin and
3-hydroxy-3-methylglutaryl-coenzyme A (HMG Co-A)
reductase inhibitors. Each patient was assigned a number
from 0–4 based on the number of medications they were
given at the time of the procedure. Each treatment and the
treatment score was analyzed by univariate Cox analysis for
the end point of death. The treatment score along with the
above mentioned covariates were then analyzed by backward
entry in a Cox multivariate model.
RESULTS
The baseline clinical characteristics of the study groups are
shown in Tables 1 and 2. Diabetic patients were older, more
often female, hypertensive, had higher NYHA classification
and Canadian Classification for unstable angina. They were
more likely to have had prior bypass surgery, greater number
of diseased vessels and lower ejection fractions. Diabetics
were less likely to be current and more likely to be past
smokers. The baseline characteristics of diabetic patients
based on proteinuria status are shown in Table 2. The
proteinuria group was more likely to be hypertensive, insulin
dependent, have a higher serum creatinine level and present
with acute MI than the nonproteinuria group. There were
only 91 gycosylated hemoglobins available for analysis
among the study groups. There were 46 for the nonprotein-
uria and 45 for the proteinuria group. The mean levels were
8.3 6 2.1 mg/dl and 8.1 6 2.4 mg/dl, respectively (p 5
0.7). The angiographic and lesion specific characteristics of
the two groups are shown in Table 3. The median left
ventricular ejection fraction was lower in the proteinuria
compared with the nonproteinuria group (50% vs. 55%, p 5
0.03), respectively. The proteinuria group was also more likely
to have a greater number of diseased vessels than the nonpro-
teinuria group, 2.3 versus 2.1, respectively (p 5 0.008).
The procedural and in-hospital outcomes are listed in
Table 4. The proteinuria group had somewhat higher rates
of in-hospital death and MI and lower rates of procedural
success and complete revascularization than the nonprotein-
uria and nondiabetic groups.
The probability of event-free survival for the study groups
is shown in Figures 1a–d. The mean follow-up time was
20.2 months. The two year mortality rate was 7.3% for
nondiabetics and 13.5% for diabetic patients (p , 0.001)
(Fig. 1a). The two-year mortality rate was 9.1% and 20.3%
for the nonproteinuria and proteinuria groups (p , 0.001)
(Fig. 1b), respectively. There was a graded increase in
mortality comparing the diabetic group stratified by pro-
teinuria status shown in Figure 1c. The two-year mortality
rate was 9.1%, 16.2% and 43.1% for the nonproteinuria, low
concentration and high concentration groups, respectively
(p , 0.001). The differences between each of these survival
curves are significant (nonproteinuria vs. low concentration,
p 5 0.009; nonproteinuria vs. high concentration, p , 0.001;
low concentration vs. high concentration, p 5 0.001). Diabet-
ics without proteinuria had similar two year mortality rates
compared with nondiabetics (9.1% vs. 7.3%, p 5 0.8) as
shown in Figure 1d.
Table 1. Baseline Characteristics of Diabetic and
Nondiabetic Patients
Diabetic
n 5 537
Nondiabetic
n 5 2,247 p
Age (yr) 64.5 6 10.0 62.7 6 10.8 0.02
Sex (male) 63.3 6 0.5 75.5 6 0.4 , 0.001
NYHA 0.5 6 1.1 0.17 6 0.6 , 0.001
Hypertension (%) 63.7 48.8 , 0.001
Current smoker (%) 11.2 19.8 ,0.001
Past smoker (%) 44.9 40.3 0.02
Unstable angina (%) 70.4 67.2 0.1
Canadian classification 3.2 6 1.2 3.1 6 1.4 , 0.001
Prior CABG (%) 36.9 29.1 0.001
LVEF 52 6 13.3 55.6 6 11.6 , 0.001
Number of diseased
vessels
2.2 6 0.8 1.89 6 0.8 , 0.001
CABG 5 coronary artery bypass grafting; LVEF 5 left ventricular ejection fraction;
NYHA 5 New York Heart Association Classification.
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The composite event rate (death, MI or revascularization)
at two years for the nonproteinuria and proteinuria groups
were 25% versus 32%, respectively (p 5 0.009). This
difference was driven by the increased mortality in the
proteinuria group. The rates of revascularization and myo-
cardial infarction were similar among the two groups. The
revascularization rate after two years was 15.8% and 11% for
the nonproteinuria and proteinuria groups, respectively (p 5
0.55). Similarly, the rate of MI among the proteinuria and
nonproteinuria groups were nearly identical (3.3% vs. 2.5%,
p 5 0.7), respectively.
The two year composite event rates for the nonprotein-
uria, low concentration and high concentration groups were
25%, 29% and 50%, respectively (p 5 0.002). The revascu-
larization rates among the three groups were 15.8%, 12.4%
and 3.4% (p 5 0.3). The rate of nonfatal MI in the high
concentration group was significantly higher than that of
the other two groups (12% vs. 2%, p 5 0.03).
The causes of death within the proteinuria and nonpro-
teinuria groups are shown in Table 5. The majority of
deaths in both groups were cardiac. There were 34 (16%)
cardiac deaths in the proteinuria group and 18 (6%) cardiac
deaths in the nonproteinuria group. There were 4 (2%)
noncardiac deaths in the proteinuria group and 3 (1%)
noncardiac deaths in the nonproteinuria group. The cause of
death could not be determined for seven patients—three in
the proteinuria group and four in the nonproteinuria group.
The baseline pharmacologic treatments are listed in Table
2. There was a trend for increased use of aspirin, beta-
blockers and HMG CoA reductase inhibitors in the non-
proteinuria group. There was a greater usage of ACE
inhibitors in the proteinuria group. Given that these drugs
have all been shown to be beneficial in patients with known
atherosclerotic coronary disease and the trend for increased
usage of three out of four agents were in the nonproteinuria
group, we sought to determine if there was any significant
treatment interaction with the end point of death for these
agents. Therefore, each of these drugs was analyzed using
univariate Cox analysis for the end point of death. This is
shown in Table 6. All drugs, with the exception of ACE
Table 2. Baseline Characteristics of Diabetic Patients based on Proteinuria Status
Proteinuria
n 5 217
Nonproteinuria
n 5 320 p†
Proteinuria
Low
Concentration
n 5 182 p‡
High
Concentration
n 5 35 p§
Age (yr) 64.7 6 10.5 64.1 6 9.7 0.49 64.9 6 10.4 0.4 63.6 6 11.1 0.5
Gender (male) 61.8 6 0.5 64.4 6 0.5 0.54 61.5 6 0.5 0.5 62.9 6 0.5 0.9
Height (cm) 168.5 6 10.4 169.8 6 10.4 0.14 168.5 6 10.4 0.2 168.3 6 10.3 0.9
Weight (kg) 86.7 6 18.3 86.0 6 18.8 0.66 87.6 6 18.7 0.4 82.5 6 15.6 0.1
Hypertension (%) 69.1 60.0 0.03 69.2 0.04 68.6 0.9
Current smoker (%) 12.0 10.6 0.63 11.5 0.8 14.3 0.6
Past smoker (%) 40.6 47.8 0.1 40.7 0.1 40.0 0.9
Unstable angina (%) 70.0 71.3 0.76 71.4 1.0 62.9 0.3
Canadian classification 3.2 6 1.3 3.2 6 1.2 0.59 3.2 6 1.3 0.4 3.3 6 1.4 0.5
Chest pain at rest (%) 27.3 31.2 0.34 30.2 0.8 10.0 0.02
Acute MI (%) 7.4 2.0 0.004 7.0 0.006 8.6 0.8
Recent MI (%) 14.7 10.6 0.15 14.3 0.2 17.1 0.7
Prior MI (%) 55.8 52.5 0.45 56.6 0.4 51.4 0.6
Prior CABG (%) 36.4 37.2 0.91 37.4 1.0 31.4 0.5
Insulin treated (%) 60.4 33.8 , 0.001 56.6 , 0.001 80.0 0.01
Laboratory Evaluation
Serum creatinine (mg/dl)* 1.0/1.0/2.0 1.0/0.6/1.0 , 0.001 1.0/1.0/2.0 , 0.001 2.0/1.9/3.0 0.002
Fasting glucose (mg/dL) 176 6 71 169 6 64 0.6 173 6 64 0.6 190 6 101 0.5
Total cholesterol (mg/dL) 215 6 48 207 6 46 0.12 211 6 49 0.5 237 6 39 0.01
Triglycerides (md/dL) 261 6 202 218 6 149 0.03 251 6 194 0.1 312 6 239 0.3
HDL (mg/dL) 34 6 10 35 6 10 0.24 34 6 10 0.4 32 6 8 0.3
LDL (md/dL) 136 6 35 130 6 33 0.1 133 6 34 0.4 152 6 40 0.06
Medication
Aspirin (%) 91.2 6 0.3 95.3 6 0.2 0.06 92.3 6 0.3 0.2 85.7 6 0.4 0.2
ACE inhibitor (%) 25.8 6 0.4 21.3 6 0.4 0.2 24.2 6 0.4 0.4 34.3 6 0.5 0.2
Beta-blocker (%) 38.2 6 0.5 47.2 6 0.5 0.04 40.7 6 0.5 0.2 25.7 6 0.4 0.1
HMG CoA (%) 12.9 6 0.3 19.1 6 0.4 0.06 13.7 6 0.3 0.1 8.6 6 0.3 0.4
Data listed as mean 6 SD, or percent of group 6 SD. *Data listed as median and interquartile range (median/lower hinge/upper hinge). †p represents comparison of
nonproteinuria and proteinuria groups. ‡p represents comparison of nonproteinuria and low concentration groups. §p represents comparison of low concentration and high
concentration groups.
ACE 5 angiotensin converting enzyme; CABG 5 coronary artery bypass grafting; HDL 5 high density lipoprotein; HMG Co A 5 HMG Co A reductase inhibitor; LDL 5
low density lipoprotein; MI 5 myocardial infarction.
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inhibitors, showed a nonsignificant trend for improved
survival in those patients receiving therapy. For ACE
inhibitors, there was a nonsignificant trend for an increased
hazard for death in those patients receiving therapy. In
order to determine the importance of combined pharmaco-
logic therapy, a treatment score based on the number of
drugs each patient was receiving at the time of intervention
was developed. Fifteen diabetics received none of the 4
drugs, 276 received only 1 drug, 326 received 2 drugs, 118
received 3 drugs and 6 received all 4 drugs. The treatment
score was significantly associated with improved survival
using univariate Cox analysis. However, as shown in Table
7B, it was not independently associated with improved
outcomes when forced into the multivariate model. Table 7,
A–B shows the results of the univariate and multivariate
Cox analysis for the end point of death for diabetic
patients. Univariate predictors of outcome are depicted in
Table 6. In this multivariate model, only proteinuria and
Table 3. Angiopgraphic and Lesion Specific Characteristics
A
B
Proteinuria
Proteinuria
n 5 217
Nonproteinuria
n 5 320 p‡
Low
Concentration
n 5 182 p¶
High
Concentration
n 5 35 p§
LVEF 50/40/65 55/45/65 0.03 50/40/65 0.06 50/40/65 0.7
Number of diseased vessels 2.3 6 0.8 2.1 6 0.8 0.008 2.2 6 0.8 0.07 2.3 6 0.8 0.8
Treatment site
LAD 35.0 6 0.5 37.2 6 0.5 0.6 35.2 6 0.5 0.7 34.3 6 0.5 0.9
Proximal LAD 16.6 6 0.4 11.3 6 0.3 0.08 17.0 6 0.4 0.07 14.3 6 0.4 0.7
Circumflex 35.0 6 .5 35.3 6 0.5 1.0 35.2 6 0.5 1.0 34.3 6 0.5 0.9
RCA 38.2 6 0.5 36.6 6 0.5 0.7 35.7 6 0.5 0.8 51.4 6 0.5 0.08
SVG 14.7 6 0.4 15.9 6 0.4 0.7 13.2 6 0.3 0.4 22.9 6 0.4 0.1
LIMA 0.9 6 0.1 1.9 6 0.1 0.4 1.0 6 0.1 0.5 0.0 6 0.0 0.5
Number of treated sites† 1/1/2 1/1/2 0.2 1/1/2 0.7 1/1/2 0.4
ACC score 2.8 6 0.9 2.7 6 0.9 0.2 2.8 6 0.9 0.2 2.8 6 1.0 0.6
Pretreatment stenosis (%) 80 82 0.2 80.4 0.3 79.6 0.7
Posttreatment stenosis (%) 28 24 0.07 28.8 0.02 26.1 0.5
PreTIMI flow 2.5 6 1.0 2.6 6 0.9 0.7 2.5 6 1.0 0.6 2.6 6 0.9 0.5
PostTIMI flow 2.8 6 0.7 2.9 6 0.6 0.2 2.8 6 0.7 0.4 2.9 6 0.6 0.4
Lesion length (mm) 9.7 6 6.4 9.0 6 5.5 0.07 9.7 6 6.3 0.4 9.5 6 7.0 0.8
Calcification score 0.5 6 0.8 0.5 6 0.8 0.9 0.4 6 0.8 0.08 0.5 6 1.0 0.3
Normal vessel diameter 2.8 6 0.6 2.9 6 0.6 0.08 2.9 6 0.6 0.6 2.7 6 0.6 0.7
Degenerated vein graft 5.1 4.1 0.6 4.9 0.6 5.7 0.8
Chronic total occlusion (%) 3.7 4.1 0.8 3.3 0.7 5.7 0.5
Balloon angioplasty (%) 69.6 61.6 0.06 69.8 0.06 68.6 0.9
Stent (%) 6.0 11.9 0.02 7.1 0.09 2.9 0.1
Rotoblator (%) 13.8 15.9 0.5 13.7 0.5 14.3 0.9
Laser (%) 0.6 0.6 0.8 0.5 0.9 0.0 0.7
TEC (%) 0.9 0.9 1.0 1.1 0.9 0.0 0.5
Data listed as mean 6 SD, or percent of group 1 SD. †Data listed as median and interquartile range (median/lower hinge/upper hinge); ‡p, represents comparison of
nonproteinuria and proteinuria groups; ¶p, represents comparison of nonproteinuria and low concentration groups; §p, represents comparison of low concentration and high
concentration groups.
ACC 5 American College of Cardiology; DCA 5 directional coronary atherectomy, rotoblater; LAD 5 left anterior descending artery; LIMA 5 left internal mammary
artery; LVEF 5 left ventricular ejection fraction; RCA 5 right coronary artery; SVG 5 saphenous vein graft; TEC 5 transluminal extraction catheter; TIMI 5 thrombolysis
in myocardial infarction.
Table 4. Procedure and In-Hospital Outcome
Nondiabetic
n 5 2,247
Proteinuria
n 5 217
Nonproteinuria
n 5 320 p*
Procedural success (%) 92 88.9 92.5 0.16
Complete revascularization (%) 25.6 13.8 19.4 0.09
In-hospital death (%) 1.8 4.2 2.8 0.39
In-hospital MI (%) 8.5 11.6 8.1 0.18
Data listed as mean percent of group 6 SD. MI 5 myocardial infarction. *p compares proteinuria and nonproteinuria groups.
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LVEF were significant predictors of death shown in
Table 7b.
DISCUSSION
Similar to other reports, our findings show that diabetic
patients have decreased survival following percutaneous
revascularization compared with nondiabetics (5,6,9). How-
ever, for the first time these data suggest that the increased
mortality is limited to those diabetics with evidence of
proteinuria on screening urinalysis. Furthermore, there is a
graded response such that patients with a high concentra-
tion of proteinuria have a nearly four-fold increase in
mortality compared with nonproteinuric diabetics. This
group also had a marked increase in nonfatal MI rate when
compared with other diabetics. The association of increas-
ing mortality with increased urinary protein concentration
further strengthens the association of proteinuria and in-
creased risk of death following percutaneous coronary re-
vascularization.
Comparison with prior studies. Proteinuria in diabetic
patients indicates underlying nephropathy and increased
risk of developing renal failure (10). Attention has been
drawn to the association of proteinuria and cardiac mortal-
Figure 1. (a– d) Probability of freedom from all-cause mortality for selected study groups.
Table 5. Cause of Death
Proteinuria
n 5 217
Nonproteinuria
n 5 320
Cardiac death (%) 34 (16) 18 (6)
Noncardiac death (%) 4 (2) 3 (1)
Unknown cause of death (%) 3 (1) 4 (1)
Data listed as number (%) of deaths for each group.
Table 6. Univariate Cox Analysis of Pharmacologic Treatment
for Two Year Death Rates among Diabetics
Hazard
Ratio 95% CI p
Beta-blockers 0.7 (0.4–1.1) 0.1
ACE inhibitors 1.1 (0.7–1.7) 0.8
Aspirin 0.6 (0.3–1.2) 0.2
HMG Co-A
reductase inhibitors
0.6 (0.3–1.2) 0.1
Treatment score 0.7 (0.6–0.98) 0.035
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ity. Patients with non-insulin dependent diabetes mellitus
(NIDDM) and proteinuria at baseline in the recent World
Health Organization (WHO) Multinational Study of Vas-
cular Disease in Diabetes had an increased risk of cardio-
vascular death three to four times that of diabetics without
proteinuria (11). In 1984, Jarret et al. and Mogensen et al.
reported an excess of all cause mortality in patients with
NIDDM and microalbuminuria (12,13). Since then, there
have been a number of longitudinal studies linking mi-
croalbuminuria and increased mortality in maturity onset
diabetes (12,14–24). However, only six cross-sectional
studies reported cardiac endpoints (16–18,20,22,23). The
cardiac endpoints were determined clinically by a history of
angina, MI or an abnormal electrocardiogram. Prior to our
study, there has been a paucity of data concerning clinical
outcomes of diabetics with proteinuria coupled with angio-
graphic data.
A great deal of attention was drawn to the strategy of
percutaneous coronary artery revascularization in diabetics
with multivessel disease after the findings of the BARI
study (7). This trial was a multicenter design randomizing
over 1,800 patients with multivessel disease to an initial
revascularization strategy of CABG or PTCA. Among
treated diabetics, the five year survival for the CABG group
was 80.6% and 65.5% for the PTCA group (p 5 0.003).
Following this trial, the National Heart Lung and Blood
Institute issued a clinical alert concluding that CABG
should be the preferred treatment for patients with treated
diabetes and multivessel disease requiring a first time
revascularization procedure (25). Given the findings of
BARI, identifying clinical predictors of poor outcome in
diabetics is fundamental to applying these findings to
clinical practice.
Proteinuria and risk assessment. These data would sug-
gest that screening diabetic patients for proteinuria by
urinalysis prior to percutaneous coronary revascularization
appears to be an effective way to risk-stratify this subset of
patients. The BARI Study showed that insulin treated
diabetics were at increased risk compared with noninsulin
treated patients. Our data would suggest that diabetics with
evidence of proteinuria, rather than insulin treated patients,
are those at highest risk for future fatal cardiac events.
Importantly, the risk of fatal events in diabetics without
proteinuria is similar to nondiabetics.
Study limitations. We were unable to analyze proteinuria
with a more sensitive assay. We identified only those
patients with macroalbuminuria with the traditional chem-
stix utilized in this study. As the sensitivity of detecting
proteinuria falls with decreasing urinary protein excretion,
newer assays have been developed to detect lower concen-
trations of proteinuria-microalbuminuria. The detection of
microalbuminuria with higher sensitivity may identify pa-
tients at increased risk after percutaneous coronary revascu-
larization. Proteinuria was determined during a period of six
months prior to three months post PCI. Therefore, non-
proteinuria patients who developed proteinuria in our
follow-up period were not reclassified. As the quantity of
proteinuria varies throughout the day, timed urinalysis may
be a more accurate way to identify high risk diabetics
undergoing revascularization. Further, a limitation of rou-
tine urinalysis is that urine volume effects the result, i.e., a
more concentrated urine sample has a higher concentration
of protein compared with a dilute sample.
Objectively characterizing the severity and duration of
diabetes is often difficult given the insidious onset of
NIDDM (26). Thus, we are left with surrogate markers of
disease severity, such as markers of glycemic control, insulin
dependence and complications of diabetes. There were only
91 glycosylated hemoglobins available for analysis among
the study patients. Although glycosylated hemoglobin was
not a predictor of outcome by univariate Cox analysis, the
lack of complete data prohibit us from making meaningful
conclusions regarding glycemic control prior to percutane-
ous coronary revascularization in our study. In this cohort of
patients, proteinuria appears to objectively identify those
patients with disease severity such that proteinuric diabetics
Table 7. Univariate and Multivariate Cox Analysis for Death
A B
Covariates
Univariate Multivariate
Hazard
Ratio 95% CI p
Hazard
Ratio 95% CI p
Proteinuria 2.3 (1.6–3.3) , 0.001 1.8 (1.1–2.9) 0.01
LVEF 1.5 (1.2–1.8) , 0.001 1.4 (1.1–1.7) 0.003
IDDM 1.9 (1.2–3.2) 0.009 1.1 (0.6–2.0) 0.7
Creatinine 7.3 (6.6–8.1) , 0.001 1.1 (0.9–1.3) 0.13
Acute MI 4.1 (1.9–8.5) , 0.001 2.5 (0.6–10.4) 0.3
Number diseased vessels 1.8 (1.3–2.5) 0.001 1.4 (0.9–2.1) 0.2
Treatment score 0.7 (0.6–0.98) 0.35 0.8 (0.6–1.2) 0.3
Tables A and B are results of Cox analysis of the listed covariates for the end point of death. Proteinuria in these tables was stratified nonproteinuria, low concentration or high
concentration. IDDM 5 insulin dependent diabetes mellitus; LVEF 5 left ventricular ejection fraction; MI 5 myocardial infarction. Hazard ratio calculated for 10% increments
with LVEF and for increments of 1 mg/dl for creatinine.
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are at increased risk for adverse outcome compared with
their nonproteinuric counterparts.
Only 23% of patients were receiving therapy with ACE
inhibitors in our study. Therapy with these agents in this
study was actually associated with increased risk of death.
This is likely secondary to selection bias. Diabetics in this
study receiving ACE inhibitors had significantly lower
ejection fractions and a high incidence of clinical heart
failure. Although ACE inhibitors have been shown to delay
the progression of proteinuria in diabetics independent of
the antihypertensive effects, they have not been shown to
abolish proteinuria or improve the cardiovascular morbidity
and mortality in diabetic patients with proteinuria (27–32).
Data from Lewis et al. demonstrated captopril therapy
reduced the risk of doubling the serum creatinine (12% in
the captopril group and 21% in the placebo group, p 5
0.007) and there was a 50% reduction in the combined
endpoints of death, dialysis and renal transplantation in the
ACE inhibitor group (31). These data were not published
until November, 1993 which likely accounts for the low
percentage of patients on ACE inhibitor therapy in our
study. Currently, the DIAB-HYCAR study is testing the
hypothesis that low dose ramipril will reduce the cardiovas-
cular morbidity and mortality in NIDDM patients with
microalbuminuria or proteinuria (33). Given that ACE
inhibitor therapy slows the progression rather than eradi-
cating proteinuria, determination of proteinuria, even in
patients receiving ACE inhibitor therapy, is likely to remain
an effective screening tool in identifying high risk diabetic
patients undergoing PCI.
Conclusions. These data support the theory that protein-
uria is a surrogate marker for advanced atherosclerosis.
Diabetic patients with proteinuria had smaller arteries, a
greater number of diseased vessels and longer lesion length
as evaluated by angiography when compared with the
nonproteinuria group. Our data suggest that the increased
mortality seen in diabetic patients is limited to those with
evidence of proteinuria and that the survival rate for
nonproteinuric diabetics is similar to nondiabetics following
PCI. Proteinuria, the determination of which is simple,
effective and inexpensive, appears to be an important prog-
nostic marker for diabetics.
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